Related content

Closed-loop insulin delivery – what lies between where we are and where we are going?

By Steil Garry M   Rebrin Kerstin  

Expert Opinion on Drug Delivery, Vol. 2, Iss. 2, 2005-03 ,pp. : 353-362

Informa Healthcare

Access to resources Recommend Favorite

Insulin Therapy in Patients with Type 2 Diabetes Mellitus: Shared Care Versus Secondary Outpatient Care in The Netherlands

By Hutubessy R.C.W.  

Disease Management & Health Outcomes, Vol. 9, Iss. 6, 2001-01 ,pp. : 337-344

Adis International

Access to resources Recommend Favorite

A Comparison of Costs among Patients with Type 2 Diabetes Mellitus Who Initiated Therapy with Exenatide or Insulin Glargine

By Misurski Derek  

Applied Health Economics and Health Policy, Vol. 7, Iss. 4, 2009-12 ,pp. : 245-254

Adis International

Access to resources Recommend Favorite

Use of Short-Acting Insulin Secretagogues for Type 2 Diabetes Mellitus: Considerations for National Health Systems

By Salas Maribel  

Disease Management & Health Outcomes, Vol. 13, Iss. 4, 2005-01 ,pp. : 219-224

Adis International

Access to resources Recommend Favorite

Adaptation – Focus on type 1 Diabetes

By  

International Journal of Child and Adolescent Health, Vol. , Iss. , 2017-01 ,pp. : 125-128

Nova Science Publishers, Inc.

Access to resources Recommend Favorite